Introduction of Salpingo-Oophoritis
In the female reproductive system, the ovary is an organ where the ovum is produced. The ovum goes down the fallopian tube into the uterus when released. The inflammation of the uterine appendage, particularly on the fallopian tubes is the disease called Salpingo-Oophoritis. It develops when staphylococci, streptococci, colon bacilli, gonococci, tubercle bacilli or other pathogens enter into fallopian tubes and the ovaries. A recent scientific report revealed that the complement component C8G is associated with Salpingo-Oophoritis and the related pathway is lectin-induced complement pathway.
Symptom
Young, sexually active women are more likely to catch Salpingo-Oophoritis. These infectious pathogens invade the fallopian tube and the tubular walls become infiltrated. The fallopian tubes and ovaries coalesce into a single inflammatory formation. The following are the conditions that lead to Salpingo-Oophoritis.
Risk Factor
Diagnosis
Oophoritis needs quick treatment to prevent health complications and preserve fertility. The seemingly mild infections can lead to severe damages to the reproductive system. The signs and symptoms are usually invisible. Therefore, the diagnosis of Oophoritis is extremely important.
Salpingo-Oophoritis may be identified by
Creative Biolabs' experts are providing high-quality biotherapeutics development services based on advanced Complement Therapeutics Platform. We offer turn-key or ala carte services customized to our client’s needs. Please feel free to contact us for detailed information.
Related Product
A: Complement regulatory proteins, like CD55 and CD59, protect host cells from excessive complement activation. In Salpingo-Oophoritis, these proteins are dysregulated, contributing to tissue damage. Developing therapeutics that restore or enhance the expression of these regulatory proteins is a potential strategy to mitigate complement-mediated damage.
A: Experimental research methods include the analysis of complement biomarkers in patient samples, in vitro cell culture studies to investigate the effects of complement inhibitors, and animal models to assess the efficacy of complement-targeted therapies.
A: Challenges include the need for extensive safety and efficacy testing, potential side effects, and the complexity of complement system regulation. Additionally, the translational process requires robust clinical trials.